Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Engineered Anti-MAGE-A T-Cells Show Early Promise

October 21st 2018

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

ESMO 2018: Dr. Verma Sheds Light on Breast Cancer Data

October 21st 2018

ESMO 2018: Dr. Ramalingam Shares Insight on Lung Cancer Studies

October 21st 2018

ESMO 2018: Dr. Abou-Alfa Discusses Updates in GI Cancer

October 21st 2018

ESMO 2018: Dr. Cohen Reflects on Practice-Changing Data in Head and Neck Cancer

October 21st 2018

ESMO 2018: Dr. George Highlights Key Abstracts in Kidney and Prostate Cancers

October 21st 2018

ESMO 2018: Dr. Moore Speaks to Exciting PARP Inhibitor Abstracts in Ovarian Cancer

October 21st 2018

OncLive News Network On Location: In Munich Monday, October 22

October 21st 2018

OncLive News Network On Location: In Munich Sunday, October 21

October 21st 2018

OncLive News Network On Location: In Munich Saturday, October 20

October 21st 2018

Improving the Management of EGFR+ NSCLC

October 20th 2018

EGFR Inhibitors as Adjuvant Therapy in NSCLC

October 20th 2018

Promising Treatment Combinations in EGFR+ NSCLC

October 20th 2018

Emerging EGFR Inhibitors in NSCLC

October 20th 2018

Managing Disease Progression in EGFR+ NSCLC

October 20th 2018

Overcoming Resistance to EGFR Inhibitors in NSCLC

October 20th 2018

Osimertinib For Uncommon EGFR Mutations in NSCLC

October 20th 2018

Significance of FLAURA in EGFR+ NSCLC

October 20th 2018

MET, EGFR C797S Linked With Acquired Resistance to Frontline Osimertinib in NSCLC

October 19th 2018

MET amplification and EGFR C797S mutations are the most commonly observed alterations associated with resistance to first-line osimertinib in patients with EGFR-mutant non–small cell lung cancer.

Dr. Halmos on Immunotherapy in Squamous NSCLC

October 18th 2018

Balazs Halmos, MD, MS, director of thoracic oncology and director of clinical cancer genomics, Montefiore Medical Center, discusses the use of immunotherapy in the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC).